IRIS UniCatt

Caldarola, Giacomo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.274
AS - Asia 3.770
EU - Europa 3.371
SA - Sud America 857
AF - Africa 130
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 6
Totale 12.424
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.139
SG - Singapore 1.921
DE - Germania 1.113
CN - Cina 965
BR - Brasile 717
SE - Svezia 480
IT - Italia 347
FR - Francia 276
UA - Ucraina 249
GB - Regno Unito 196
VN - Vietnam 189
FI - Finlandia 173
IE - Irlanda 160
ID - Indonesia 123
IN - India 122
RU - Federazione Russa 87
PL - Polonia 84
CA - Canada 63
AR - Argentina 61
HK - Hong Kong 61
IQ - Iraq 55
BD - Bangladesh 54
TR - Turchia 47
JP - Giappone 42
MX - Messico 42
KR - Corea 40
AT - Austria 33
ES - Italia 31
ZA - Sudafrica 30
EG - Egitto 28
NL - Olanda 28
BE - Belgio 27
EC - Ecuador 25
CI - Costa d'Avorio 23
MA - Marocco 19
PK - Pakistan 17
SA - Arabia Saudita 17
LT - Lituania 14
AE - Emirati Arabi Uniti 13
VE - Venezuela 13
CZ - Repubblica Ceca 12
JO - Giordania 12
MY - Malesia 12
PE - Perù 12
UZ - Uzbekistan 12
RO - Romania 11
KE - Kenya 10
KZ - Kazakistan 9
NZ - Nuova Zelanda 9
IR - Iran 8
PT - Portogallo 8
PY - Paraguay 8
AU - Australia 7
HN - Honduras 7
TN - Tunisia 7
AL - Albania 6
AZ - Azerbaigian 6
CL - Cile 6
CO - Colombia 6
PA - Panama 6
PH - Filippine 6
IL - Israele 5
KG - Kirghizistan 5
NP - Nepal 5
BO - Bolivia 4
DK - Danimarca 4
EU - Europa 4
GR - Grecia 4
HU - Ungheria 4
NO - Norvegia 4
CH - Svizzera 3
CY - Cipro 3
DZ - Algeria 3
ET - Etiopia 3
HR - Croazia 3
LA - Repubblica Popolare Democratica del Laos 3
LK - Sri Lanka 3
MD - Moldavia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
BG - Bulgaria 2
BN - Brunei Darussalam 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
GT - Guatemala 2
GY - Guiana 2
JM - Giamaica 2
LB - Libano 2
LU - Lussemburgo 2
OM - Oman 2
PS - Palestinian Territory 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
DM - Dominica 1
Totale 12.411
Salva come PNG Salva come JPEG
Città #
Singapore 840
Chandler 682
Ashburn 434
Dallas 251
Beijing 195
Dublin 156
New York 148
Jacksonville 146
Hefei 143
San Mateo 133
Jakarta 112
Los Angeles 110
Munich 101
Nanjing 94
Wilmington 84
Ann Arbor 79
Boston 76
Helsinki 75
Rome 74
São Paulo 72
Houston 69
Milan 69
Frankfurt am Main 67
Woodbridge 67
Dearborn 63
Ho Chi Minh City 61
Hong Kong 59
The Dalles 59
Bremen 57
Cattolica 48
Nürnberg 48
Hanoi 47
Princeton 46
North Bergen 45
Boardman 42
Kent 42
Lawrence 42
Moscow 42
Kraków 41
Seoul 36
London 34
Turku 33
Nanchang 32
Seattle 32
Redwood City 31
Warsaw 30
Chicago 28
Paris 28
Tokyo 28
Marseille 27
Rio de Janeiro 27
Brooklyn 26
Fairfield 26
Brussels 24
Nuremberg 24
Abidjan 23
Düsseldorf 23
Montreal 23
Poplar 23
Curitiba 22
Denver 22
Santa Clara 22
Baghdad 21
Atlanta 20
Leawood 19
Vienna 19
Kunming 18
Brasília 17
Buffalo 17
Hebei 17
Hyderabad 17
Redmond 17
Detroit 16
Stockholm 16
Johannesburg 15
Shanghai 15
Tianjin 15
Ankara 14
Norwalk 14
Amsterdam 13
Phoenix 13
Shenyang 13
Amman 12
Belo Horizonte 12
Izmir 12
Mexico City 12
Cairo 11
Changsha 11
Lappeenranta 11
Orem 11
Roubaix 11
Toronto 11
Augusta 10
Falkenstein 10
Guangzhou 10
Jiaxing 10
Lauterbourg 10
Mountain View 10
Tashkent 10
University Park 10
Totale 6.163
Salva come PNG Salva come JPEG
Nome #
Psoriatic patients have an increased risk of polycystic ovary syndrome: results of a cross-sectional analysis. 211
Anti-TNF-α-induced psoriasiform lesions in IBD: an abnormal immune activation or a 'patchy cutaneous' immune suppression? 196
Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study. 181
Infliximab monotherapy in neuro-Behçet's disease: four year follow-up in a long-standing case resistant to conventional therapies 169
Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis 169
Linear atrophoderma of Moulin 168
Psoriasis and polycystic ovary syndrome: a new link in different phenotypes 157
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study 156
Exacerbation of pemphigus after influenza vaccination. 152
Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: preliminary data. 148
Tumour necrosis factor-related apoptosis-inducing ligand (trail): a possible pathogenic role in chronic plaque psoriasis 146
Usefulness of ultrasound imaging in detecting psoriatic arthritis of fingers and toes in patients with psoriasis. 145
A glass of red wine to keep vascular disease at bay, but what about pemphigus vulgaris? 144
Circulating endothelial cell levels in psoriatic patients and their modification after an anti-TNF-alpha (Etanercept) treatment 142
HLA-Cw6 allele, NFkB1 and NFkBIA polymorphisms play no role in predicting response to etanercept in psoriatic patients 142
Infliximab monotherapy in neuro-Behçet's disease: four year follow-up in a long-standing case resistant to conventional therapies 140
Clinical and ultrasonographic profile of adalimumab-treated hidradenitis suppurativa patients: A real-life monocentric experience 139
Enteric-coated mycophenolate sodium as a steroid-sparing agent in pemphigus treatment: a retrospective study 138
Circumscribed pityriasis rubra pilaris type IV 136
Evaluation of Endothelial Dysfunction in Psoriatic Patients by Different Techniques 135
Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study 133
Management of recurrent cutaneous abscesses during therapy with infliximab 132
Lichenoid reaction induced by adalimumab 129
Bullous pemphigoid in a transplant recipient: is this a sign of allograft rejection? 127
Clinical predictors of nonresponse to anti-TNF-α agents in psoriatic patients: A retrospective study 123
Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports 123
Etanercept therapy for psoriasis in a patient with numerous comorbidities 122
TNF-alpha gene polymorphisms can help to predict response to etanercept in psoriatic patients 121
TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept 120
IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses 119
Bullous pemphigoid in a transplant recipient: is this a sign of allograft rejection? 116
TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept 116
development of pemphigus vulgaris in a patient with psoriasis treated with cyclosporine 114
Dyshidrosiform pemphigoid: a well-defined clinical entity? 113
Psoriasis and erythema nodosum: two comorbidities of inflammatory bowel diseases 112
Melanoma and non-melanoma skin cancer in psoriatic patients treated with high-dose phototherapy 111
Psychopathology and eating disorders in patients with psoriasis 108
Therapeutic impact and management of persistent head and neck atopic dermatitis in dupilumab-treated patients 108
Clinical, histopathological, and immunological evaluation of a series of patients with erythema nodosum 106
Bullous pemphigoid in a transplant recipient: is this a sign of allograft rejection? 105
Human leukocyte antigen-B*58:01 allele in a familial case of Stevens-Johnson syndrome induced by allopurinol 105
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation 105
Clinico-dermoscopic features of alopecia areata in patients with psoriasis 104
Tumour necrosis factor-related apoptosis-inducing ligand (trail): a possible pathogenic role in chronic plaque psoriasis 103
Melanoma onset after estrogen, thyroid, and growth hormone replacement therapy. 99
Lichen sclerosus of the glans simulating melanoma 98
Herpes simplex virus infection in pemphigus vulgaris: clinical and immunological considerations 97
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature 97
Dermoscopy of cutaneous sarcoidosis. 96
Biological agents targeting interleukin-13 for atopic dermatitis 96
Role of personalized medication training in improving efficacy and adherence to a topical therapy 95
Ixekizumab exposure associated with myelitis: A case report and a literature review 95
A case of linear immunoglobulin A bullous dermatosis in a patient exposed to sun and an analgesic 94
Psoriasis and polycystic ovary syndrome: A new link in different phenotypes 94
Childhood trauma and resilience in psoriatic patients: A preliminary report 90
New onset of remitting seronegative symmetrical synovitis with pitting oedema and palmoplantar psoriasis flare-up after Sars-Cov-2 vaccination 89
The preclinical discovery and development of deucravacitinib for the treatment of psoriasis 87
Dermoscopy of melanocytic lesions in patients affected by oculocutaneous albinism: a case series 87
New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis 86
Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy 86
Clinical, epidemiological, and therapeutic hallmarks of pyoderma gangrenosum: a case series of 35 patients 83
Untreated Psoriasis Impairs Male Fertility: A Case-Control Study 83
Childhood trauma and resilience in psoriatic patients: A preliminary report. 82
Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice 82
Drug survival of biologics and non-biologics in patients affected by palmoplantar psoriasis: a “real-world”, mono-center experience 81
Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy 81
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry 80
Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: A 52-week Italian real-life experience 79
Line-field confocal optical coherence tomography in alopecia areata and histopathological correlation 78
Dermoscopy of necrobiosis lipoidica and granuloma annulare 78
Anti-TNF-α-induced psoriasiform lesions in IBD: An abnormal immune activation or a 'patchy cutaneous' immune suppression? 78
Successful treatment with tralokinumab in patients with atopic dermatitis and dupilumab-induced psoriasis 77
Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment 76
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis) 75
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study 75
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study 74
Linear IgA bullous dermatosis and ulcerative colitis treated by proctocolectomy 74
Psoriasis and erythema nodosum: two comorbidities of inflammatory bowel diseases 74
A possible role of polycystic ovary syndrome for pregnancy complications in women with psoriasis 74
Granuloma faciale: a case report on long-term treatment with topical tacrolimus and dermoscopic aspects 74
Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study 73
A case of chronic disseminated lupus erythematosus in a psoriatic patient receiving ustekinumab 72
Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24-week Italian study 71
Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study–IL PSO (Italian Landscape Psoriasis) 71
Living with chronic spontaneous urticaria in Italy: A narrative medicine project to improve the pathway of patient care 71
IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses 70
Prevalence of cutaneous comorbidities in psoriatic patients and their impact on quality of life. 69
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy 69
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER–study) 68
Anti-IL-17 monoclonal antibodies and bullous pemphigoid: treatment or causal agents? A case series and review of the literature 67
Low grade of satisfaction related to the use of current systemic therapies among pustular psoriasis patients: a therapeutic unmet need to be fulfilled 67
2-Year Experience with Risankizumab in the Treatment of Plaque Psoriasis in Lazio Region, Italy 66
A case of eczematous eruption occurring during treatment with risankizumab 66
Multiple eruptive plaque-like dermatofibromas during anti-TNFα treatment 64
Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study 64
Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis) 63
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study 63
Evaluation of the Impact of Night Shift Work on Disease Severity in Psoriatic Patients: A Case-Control Study with Clinical, Hormonal, and Immunological Evaluation 63
A possible role of polycystic ovary syndrome for pregnancy complications in women with psoriasis 61
Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study 61
Totale 10.272
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.521
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.521
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021302 0 0 0 0 0 24 51 40 63 16 100 8
2021/2022671 75 55 20 19 35 21 10 113 17 40 129 137
2022/20231.787 219 255 118 281 145 222 64 139 238 22 60 24
2023/2024990 41 237 42 136 30 125 57 45 16 36 121 104
2024/20252.496 59 60 179 67 183 169 71 117 392 213 571 415
2025/20264.142 927 196 589 903 1.227 300 0 0 0 0 0 0
Totale 12.568